NexPoint, a multibillion-dollar alternative investment firm, has launched NexPoint Life Sciences III DST, a Delaware Statutory Trust (the DST), which acquired a life sciences industrial manufacturing property in Woodbury, Minn. The DST seeks to raise approximately $31 million through the offering. The investment reinforces NexPoint’s commitment to life sciences real estate, which continues to be a key area of growth across NexPoint’s real estate platform.
The approximately 138,000-square-foot property is the global headquarters for Kindeva Drug Delivery, a contract development and manufacturing organization (CDMO) that develops and manufactures products across a range of complex drug-delivery formats. The property is a research, formulation, and development facility for the tenant, which offers clinical manufacturing space, development laboratory space, and a range of features and capabilities to support drug delivery solutions. The DST investment benefits from having